Advanced Molecular Diagnostic Systems

1 Dalmore Drive, Scoresby, Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817 www.generabiosystems.com

8 January 2013 ASX Announcement - GENERA BIOSYSTEMS LIMITED (ASX:GBI) - SHARE PLACEMENT - Notice under section 708A(5)(e) of the Corporations Act 2001


Genera Biosystems Limited (Issuer) issued on 31 December 2012 7,619,045 fully paid ordinary shares (Shares) in the company at an issue price of $0.105 per Share under a placement made to sophisticated and professional investors, as announced on 18 December 2012.
The Issuer advises that:
(a) the Shares were issued by the Issuer without disclosure to investors under Part 6D.2 of the
Corporations Act 2001 (Act);
(b) this notice is being given under section 708A(5)(e) of the Act; (c) as at the date of this notice, the Issuer has complied with:
(i) the provisions of Chapter 2M of the Act, as they apply to the Issuer; and
(ii) section 674 of the Act; and
(d) as at the date of this notice, there is no information that is 'excluded information' within the
meanings of sections 708A(7) and 708A(8) of the Act.

For further information please contact:
Mr Lou Panaccio
Executive Chairman
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
Lou.Panaccio@generabiosystems.com

About Genera Biosystems:

Genera Biosystems Limited (ASX: GBI) is a molecular diagnostics company that develops, manufactures and distributes advanced molecular diagnostic tests. Its first product, PapType®, a test which simultaneously detects and genotypes human papillomavirus, is registered in Australia and
the European Union.

distributed by